APGE
Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. (APGE) has 7 SEC Form 4 filings (12 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Jul 17, 2026.
The most active filer is Chief Medical Officer Dambkowski Carl with 3 filings. Insiders have net sold $18.1M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Michael Thomas Henderson
- Employees:196
- HQ:Waltham, MA, US
- IPO:2023-07-14
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$18.1M
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Market Cap
$10.0B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Executive Officer | Sale | 20,000 | $2.7M | Jul 11 | SEC ↗ | |
| Chief Medical Officer | Sale | 5,500 | $730K | Jul 2 | SEC ↗ | |
| Chief Medical Officer | Sale | 26,400 | $3.5M | Jun 25 | SEC ↗ | |
| Chief Executive Officer | Sale | 80,000 | $10.6M | Jun 25 | SEC ↗ | |
| Chief Medical Officer | Sale | 5,500 | $433K | Jun 6 | SEC ↗ | |
Henderson JaneFirst filing | Chief Financial Officer | Sale | 2,000 | $164K | May 5 | SEC ↗ |
Related companies
Apogee Therapeutics, Inc. is in the Healthcare sector.